
    
      Each participant will participate in 2 treatment periods separated by a washout of at least 5
      days between investigational product (IP) administration in each period. Participants will be
      admitted to the clinical unit on day -1 of period 1 and will be in clinical unit for periods
      1 and 2. On day 1 of each period, participants will receive fezolinetant followed by a
      72-hour blood sampling period. The study will be completed with an end-of-study visit (ESV)
      which will take place 5 to 9 days after the 72-hour blood sampling period in period 2 or at
      the time of early discontinuation from the study.
    
  